The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/-Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments

被引：25
作者：
Serrano, Dolores [1 ]
Torrado, Susana [1 ]
Torrado-Santiago, Santiago [1 ]
Gisbert, Javier P. [2 ]
机构：
[1] Univ Complutense, Fac Farm, Dept Pharmaceut Technol, E-28040 Madrid, Spain
[2] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IP, Dept Gastroenterol, Madrid, Spain
来源：
CURRENT DRUG METABOLISM | 2012年 / 13卷 / 09期
关键词：
CYP2C19; genetic polymorphism; Helicobacter pylori eradication; proton pump inhibitor; rabeprazole; omeprazole; lansoprazole; pantoprazole; esomeprazole; CYTOCHROME-P450; ENZYMES; 2C9; 1-WEEK TRIPLE THERAPY; RANDOMIZED OPEN TRIAL; ERADICATION RATE; CURE RATES; OMEPRAZOLE METABOLISM; GENOTYPIC DIFFERENCES; DRUG-METABOLISM; DUAL THERAPY; RABEPRAZOLE;
D O I：
10.2174/138920012803341393
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Proton pump inhibitors (PPIs) are the most potent acid suppressants available. PPIs undergo hepatic metabolism via the CYP2C system for the isoforms CYP2C19 and CYP3A4 in particular. Genetic polymorphisms in CYP2C19 may affect the metabolism of individual PPIs to different extents. Although PPIs are highly effective as a class, differences in their pharmacokinetics, such as bioavailability and metabolism, may translate into differences in clinical outcomes. In Helicobacter pylori infection, a significantly lower eradication rate was seen in extensive metabolizers with omeprazole but no with rabeprazole.
引用
收藏
页码：1303 / 1312
页数：10
相关论文
共 50 条
  • [41] Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese
    Sugimoto, Mitsushige
    Shirai, Naohito
    Nishino, Masafumi
    Kodaira, Chise
    Uotani, Takahiro
    Sahara, Shu
    Ichikawa, Hitomi
    Kagami, Takuma
    Sugimoto, Ken
    Furuta, Takahisa
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (09) : 1073 - 1078
  • [42] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
    Chang‑Keun Cho
    Ji-Young Byeon
    Pureum Kang
    Hye-Jung Park
    Eunvin Ko
    Chou Yen Mu
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Archives of Pharmacal Research, 2023, 46 : 111 - 116
  • [43] Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism
    Lou, Horng-Yuan
    Chang, Chun-Chao
    Sheu, Ming-Thau
    Chen, Ying-Chen
    Ho, Hsiu-O
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (01) : 55 - 64
  • [44] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers
    Shao, H.
    Ren, X. M.
    Liu, N. F.
    Chen, G. M.
    Li, W. L.
    Zhai, Z. H.
    Wang, D. W.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (03) : 351 - 360
  • [45] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Zalloum, Imad
    Hakooz, Nancy
    Arafat, Tawfiq
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (04) : 4195 - 4200
  • [46] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Imad Zalloum
    Nancy Hakooz
    Tawfiq Arafat
    Molecular Biology Reports, 2012, 39 : 4195 - 4200
  • [47] [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole
    Furuta, T.
    Kodaira, C.
    Nishino, M.
    Yamade, M.
    Sugimoto, M.
    Ikuma, M.
    Hishida, A.
    Watanabe, H.
    Umemura, K.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (03) : 294 - 300
  • [48] Correlation of CYP2C19 Genetic Polymorphisms With Helicobacter pylori Eradication in Patients With Cirrhosis and Peptic Ulcer
    Lay, Chii-Shyan
    Lin, Jiun-Rong
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2010, 73 (04) : 188 - 193
  • [49] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Kang, Pureum
    Cho, Chang-Keun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    Choi, Chang-Ik
    Bae, Jung-Woo
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (05) : 438 - 447
  • [50] The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects
    Bo Tan
    Yi-Fan Zhang
    Xiao-Yan Chen
    Xiao-Hua Zhao
    Guo-Xin Li
    Da-Fang Zhong
    European Journal of Clinical Pharmacology, 2010, 66 : 145 - 151
12345